Published in final edited form as:

Bioorg Med Chem Lett. 2007 April 15; 17(8): 2285–2288. doi:10.1016/j.bmcl.2007.01.074.

An analogue of AICAR with dual inhibitory activity against WNV and HCV NTPase/helicase: Synthesis and *in vitro* screening of 4-carbamoyl-5-(4,6-diamino-2,5-dihydro-1,3,5-triazin-2-yl)imidazole-1- β -D-ribofuranoside

Ravi K. Ujjinamatada^a, Andrea Baier^b, Peter Borowski^b, and Ramachandra S. Hosmane^{a,*}

^a *Laboratory for Drug Design and Synthesis, Department of Chemistry and Biochemistry, University of Maryland, Baltimore County, 1000 Hilltop Circle, Baltimore, Maryland 21250, USA* ^b *The Faculty of Mathematics & Natural Sciences, The John Paul II Catholic University of Lublin, 20-718 Lublin, Poland*

Abstract

The title compound (**4**) was synthesized by the reaction of ethyl 1-(2,3,5-tri-*O*-benzoyl- β -D-ribofuranosyl)-5-formylimidazole-4-carboxylate with excess guanidine in ethanol at reflux. Compound **4** was evaluated *in vitro* against NTPases/helicases of four different viruses of the *Flaviviridae* family, including the West Nile virus (WNV), hepatitis C virus (HCV), dengue virus (DENV), and the Japanese encephalitis virus (JEV), employing both an RNA and a DNA substrate. The compound showed activity against NTPase/helicase of WNV and HCV with an IC₅₀ of 23 and 37 μ M, respectively, when a DNA substrate was employed, while no activity was observed when an RNA substrate was used. There was no activity against the NTPase/helicase of either DENV or JEV irrespective of whether an RNA or a DNA substrate was employed. Considering that *Flaviviridae* are RNA viruses, the observed absence of activity against an RNA substrate, but the presence of activity against a DNA substrate is intriguing and somewhat surprising. The preliminary studies show that compound **4** does not form a tight complex with either an RNA or a DNA substrate, suggesting that its mechanism of action may involve direct interaction with the enzyme.

Keywords

AICAR analogue; synthesis; *in vitro* screening; inhibition of *Flaviviridae* NTPase/helicase; West Nile virus (WNV) and hepatitis C virus (HCV)

We have recently reported¹ the synthesis of novel imidazole analogues (III) from the corresponding imidazoles (I), employing an interesting functional group transformation² mediated by guanidine (Scheme 1). We also reported that compound III (R=Deoxyribosyl) exhibited a potent *in vitro* inhibitory activity against the West Nile Virus (WNV) NTPase/helicase when an RNA substrate was employed, but no activity with a DNA substrate.¹ Since WNV is an RNA virus, the observed inactivity with a DNA substrate was not too surprising, but instead gave further impetus to synthesize and screen the ribose analogue of III (R=ribosyl)

*Corresponding author. Tel.: +1 410 455 2520; fax: +1 410 455 1148; e-mail: E-mail: hosmane@umbc.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

against not only WNV^{3–5} but also a few other similarly dreadful viruses belonging to the same *Flaviviridae* family, which are of current global health threat, including the hepatitis C virus (HCV),^{6–11} dengue virus (DENV),^{12–16} and the Japanese encephalitis virus (JEV).^{17–20}

Synthesis of the target nucleoside **4** (Scheme 2) commenced from ethyl 5-diethoxymethylimidazole-4-carboxylate **1**.^{1,21,22} The latter was converted into its sodium salt using sodium hydride in acetonitrile, and was further reacted with 2,3,5-tri-*O*-benzoyl- β -D-ribofuranosyl-1-iodide under standard conditions of glycosylation (acetonitrile/50 °C/2h).^{21,23} The iodide itself was prepared by reaction of 1-acetyl-2,3,5-tri-*O*-benzoyl- β -D-ribofuranose and iodotrimethylsilane at room temperature in benzene.²⁴ The glycosylation procedure is known to be stereospecific giving predominantly the β -anomeric product.^{24,25} The product ethyl 1-(2,3,5-tri-*O*-benzoyl- β -D-ribofuranosyl)-5-(diethoxymethyl)imidazole-4-carboxylate (**2**) was isolated in 87% yield. The acetal **2** was reacted with 80% aqueous acetic acid to obtain the corresponding carboxaldehyde **3** in 78% yield. The reaction of the latter with excess guanidine in ethanol at reflux for 12 hours provided the target nucleoside **4**. All intermediates as well as the final compound were fully characterized by spectroscopic and microanalytical data.²⁶ Compound **4** can be considered as an analogue of 5-aminoimidazole-4-carboxamide-1- β -D-ribofuranoside (AICAR), an important biosynthetic precursor of purine nucleosides, with a diaminodihydrotriazine substituent replacing the 5-amino group of AICAR.

The NTPases/helicases from four closely related *Flaviviridae*, including the West Nile virus (WNV), hepatitis C virus, Japanese encephalitis virus (JEV), and dengue virus (DENV) were employed for the helicase inhibition studies. The WNV NTPase/helicase was isolated and purified from the cell culture medium harvested from virus-infected Vero E6 cells as described by us previously.^{27–30} The NTPase/helicase domains of HCV,^{31,32} JEV,³³ and DENV³⁴ NS3 were expressed in *E. coli* and purified according to the protocol for the HCV enzyme, which we reported earlier.²⁷ The compound was tested against both RNA and DNA substrates consisting of two annealed RNA or DNA oligonucleotides. The unwinding activity of the enzyme was assessed by monitoring the release of the shorter labeled strand of the RNA or DNA duplex, employing the protocol as described.^{27,28} The helicase activity was calibrated with an RNA or a DNA substrate that was unwound at an ATP concentration equal to the K_M value determined for the NTPase reaction.^{27,28} The anti-helicase activity of Nucleoside **4** against the mentioned four different NTPases/helicases is listed in Table 1 employing a DNA substrate.

However, no inhibition could be detected when the same experiments were repeated using an RNA substrate. As *Flaviviridae* are RNA viruses, the observed results are intriguing, especially considering that the 2'-deoxyribose analogue of **4** (*i.e.*, **III**; R=deoxyribosyl in Scheme I) has shown activity against the NTPase/helicase of WNV with an RNA substrate, but no activity against a DNA substrate as we reported recently.¹ The significance and implications of the observed contrasting results between the ribose analogue **4** and its 2'-deoxy counterpart with respect to an RNA or DNA substrate of viral helicase are not clear at the moment.

Since the observed antiviral activity of **4** against NTPase/helicase is very specific to the type of nucleic acid (DNA *versus* RNA) substrate employed, we wondered if the mechanism of action of **4** is dependent upon its ability to form a tight complex with a DNA substrate but not with RNA. There are many documented reports demonstrating non-covalent, tight-binding interactions of analogues of nucleobases, nucleosides, and nucleotides, which simply bind to major or minor grooves of DNA or RNA double helices.^{35,36} We ourselves have recently reported such interactions with some ring-expanded nucleoside (REN) analogues that were found to form tight complexes with DNA or RNA substrates of viral helicases, as evidenced by the observed complete stability of the complexes in the presence of 0.5% sodium dodecyl sulfate (SDS) as well as by the observed severe hindrance to migration of the DNA or RNA

substrates in TBE-polyacrylamide gel electrophoresis in the presence of REN analogues with or without the enzyme being present.^{27,28} By contrast, and to our surprise, no such tight complex formation was observed with either a DNA or an RNA substrate when the same experiments were conducted using the nucleoside analogue **4**. This observation is indeed exciting as it implies that the compound must be interacting directly with the enzyme. The observed difference in activity resulting from the different types of substrates employed may well be due either to the differential conformational effects exerted by the enzyme-substrate complex upon subsequent binding of the inhibitor to the protein or due to those caused by the enzyme-inhibitor complex upon eventual binding of a DNA or an RNA substrate. These speculations, however, are only tentative at this point.

Acknowledgements

The research was supported in part by grants (# 5 RO1 AI55452 & #1 R21 AI071802) from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, Bethesda, Maryland, and by an unrestricted grant from Nabi Biopharmaceuticals, Rockville, Maryland.

References and notes

1. Ujjinamatada RK, Agasimundin YS, Zhang P, Hosmane RS. Nucleosides Nucleotides Nucleic Acids 2005;24:1775. [PubMed: 16438047]
2. Ujjinamatada RK, Hosmane RS. Tetrahedron Lett 2005;46:6005.
3. Diamond MS, Klein RS. Trends Microbiol 2006;14:287. [PubMed: 16750369]
4. Davis LE, DeBiasi R, Goade DE, Haaland KY, Harrington JA, Harnar JB, Pergam SA, King MK, DeMasters BK, Tyler KL. Ann Neurol 2006;60:286. [PubMed: 16983682]
5. Hayes EB, Gubler DJ. Annu Rev Med 2006;57:181. [PubMed: 16409144]
6. Dufour DR. Molecular Diagnostics (2nd Edition) 2006:461.
7. Toniutto P, Fabris C, Pirisi M. Expert Opin Pharmacother 2006;7:2025. [PubMed: 17020430]
8. MacDonald A, Harris M. Liver Dis 2006;2:439.
9. Neyts J. Antiviral Res 2006;71:363. [PubMed: 16843538]
10. Huang Z, Murray MG, Secrist JA. Antiviral Res 2006;71:351. [PubMed: 16828888]
11. Pol S, Mallet VO. Expert Opin Biol Ther 2006;6:923. [PubMed: 16918259]
12. Fink J, Gu F, Vasudevan SG. Rev Med Virol 2006;16:263. [PubMed: 16791836]
13. Lin CF, Wan SW, Cheng HJ, Lei HY, Lin YS. Viral Immunol 2006;19:127. [PubMed: 16817755]
14. Green S, Rothman A. Curr Opin Infect Dis 2006;19:429. [PubMed: 16940865]
15. Chaturvedi U, Nagar R, Shrivastava R. FEMS Immunol Med Microbiol 2006;47:155. [PubMed: 16831202]
16. Seneviratne SL, Malavige GN, de Silva HJ. Trans R Soc Trop Med Hyg 2006;100:608. [PubMed: 16483623]
17. Parida M, Dash PK, Tripathi NK, Ambuj, Saxena P, Agarwal S, Sahni AK, Singh SP, Rath AK, Bhargava R, Abhyankar A, Verma SK, Lakshmana Rao PV, Sekhar K. Emerging Infect Dis 2006;12:1427. [PubMed: 17073095]
18. Chen SO, Chang TJ, Stone G, Chen CH, Liu JJ. Intervirology 2006;49:346.
19. Arya SC, Agarwal N. Vaccine 2006;24:5108. [PubMed: 16713036]
20. Abe M, Shiosaki K, Hammar L, Sonoda K, Xing L, Kuzuhara S, Kino Y, Cheng RH. Virus Res 2006;121:152. [PubMed: 16815584]
21. Ramesh K, Panzica RP. J Chem Soc Perkin Trans 1;1989:1769.
22. Murakami T, Otsuka M, Ohno M. Tetrahedron Lett 1982;23:4729.
23. Kazimierczuk Z, Cottam HB, Revankar GR, Robins RK. J Am Chem Soc 1984;106:6379.
24. Tocik Z, Earl RA, Beranek J. Nucleic Acids Res 1980;8:4755. [PubMed: 7443524]
25. Marquez VE, Liu PS, Linevsky JK. J Org Chem 1982;47:1712.

26. Experimental: Preparation and physicochemical properties of the compounds are as follows: *Ethyl 5-Diethoxymethyl-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)imidazole-4-carboxylate (2)*. *Step 1: Preparation of sodium salt of ethyl 5-diethoxymethyl-imidazole-4-carboxylate*: To a solution of ethyl 5-diethoxymethylimidazole-4-carboxylate (0.267 g, 1 mmol) in dry acetonitrile (10 mL), sodium hydride (80 mg, 2 mmol) was added and the mixture was stirred at room temperature under nitrogen atmosphere for 30 min. *Step 2: Reaction of sodium salt of ethyl 5-diethoxymethyl-imidazole-4-carboxylate with 1-O-acetyl-2,3,5-O-benzoyl-β-D-ribofuranosyl iodide*: To a solution of 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (0.567 g, 1 mmol) in dry benzene (5 mL), iodotrimethylsilane (0.225 mL, 1.6 mmol) was added dropwise. The mixture was swirled for 10 min at room temperature and then it was added dropwise to a stirred suspension of the above sodium salt of ethyl 5-diethoxymethylimidazole-4-carboxylate. The temperature of the reaction mixture was gradually raised to 50 °C and was stirred for 2h. The reaction mixture was then brought to room temperature, acetonitrile was removed under vacuum, and the residue was purified by column chromatography using hexanes: ethyl acetate (3:1) as an eluting solvent. Appropriate fractions were pooled and evaporated under vacuum. Gummy residue was crystallized from benzene-pet ether to obtain colorless, flaky solid. Yield 0.595 g, 87 %; mp 43–45 °C, Rf = 0.21 (hexanes: ethyl acetate 3:1); IR, 1718, 1703, 1577, 1501 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.1 (m, 7H, Ar-H and imidazole CH), 7.59–7.29 (m, 9H, Ar-H), 6.82 (d, *J* = 3.9 Hz, 1H, 1'-H), 6.37 (s, 1H, CH), 5.60 (m, 2H, 2'-H, and 3'-H), 4.8–4.4 (m, 3H, 4'-, 5'- and 5''-H), 4.40 (q, *J* = 1.8 Hz, 2H), 3.85–3.45 (m, 4H, 2 CH₂, 1.39 (t, *J* = 6.9 Hz, 3H, CH₃), 1.19 (t, *J* = 7.2 Hz, 3H, CH₃), 1.02 (t, *J* = 6.9 Hz, 3H, CH₃); HRMS (FAB) calcd. for C₃₇H₃₈N₂O₁₁, 687.2554 (MH⁺); observed *m/z* 687.2562 (MH⁺). *Ethyl 5-formyl-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)imidazole-4-carboxylate (3)*: A solution of ethyl 5-diethoxymethyl-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)imidazole-4-carboxylate (0.515 g 0.75 mmol) in 80% aqueous acetic acid (5 mL) was stirred at room temperature for 15 h. The solution was then poured into ice-water (25 mL) and the precipitated solid was extracted with chloroform (3×50 mL). The chloroform layer was washed with water (2×25 mL) and dried over anhy. sodium sulfate. The solvent was removed under vacuum and the residue was purified by flash chromatography on silica gel, using hexanes: ethyl acetate (2:1) as an eluting solvent. Appropriate fractions were pooled and evaporated under vacuum. The residue was triturated with methanol to obtain a white solid. Yield 0.360 g, 78%; mp 167–169 °C, Rf = 0.34 (hexanes: ethyl acetate 2:1); IR 1729, 1706, 1532, 1480 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 10.5 (s, 1H, CHO), 8.17 (s, 1H, imidazole CH), 8.08–7.90 (m, 6H, Ar-H), 7.62–7.32 (m, 9H, Ar-H), 6.92 (d, *J* = 4.5 Hz, 1H, 1'-H), 5.88–5.76 (m, 2H, 2'-H, and 3'-H), 4.89–4.41 (m, 3H, 4'-, 5'- and 5''-H), 4.40 (q, *J* = 7.2 Hz, 2H), 1.42 (t, *J* = 6.9 Hz, 3H, CH₃); HRMS (FAB) calcd. for C₃₃H₂₈N₂O₁₀, 613.1822 (MH⁺); observed *m/z* 613.1828 (MH⁺). *5-(4,6-Diamino-2,5-dihydro-1,3,5-triazin-2-yl)-1-(β-D-ribofuranosyl)-imidazole-4-carboxamide (4)*: Guanidine hydrochloride (0.192 g, 2 mmol) was neutralized with a solution of sodium (46 mg, 2 mmol) in anhy. ethanol (5 mL) by stirring at 5 °C for 30 min. The precipitated sodium chloride was removed through filtration and the filtrate was added to a solution of ethyl 5-formyl-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)imidazole-4-carboxylate (0.307 g, 0.5 mmol) in dry ethanol (10 mL). The reaction mixture was heated at reflux for 12 h. The reaction mixture was cooled, mixed with flash silica gel (2 g), and the solvent was evaporated. The residue was purified by flash chromatography, using a mixture of chloroform-methanol: ammonium hydroxide (1:1:0.25) as an eluting solvent. The appropriate fractions were pooled and the solvents were removed under vacuum to obtain a colorless solid. Yield 0.108 g, 61%; mp 144–146 °C, Rf = 0.24 (chloroform: methanol: ammonium hydroxide, 1:1:0.25); IR 3341, 3305, 3296, 1647, 1621 cm⁻¹; ¹H NMR (DMSO-*d*₆, 300 MHz) δ 8.03 (s, 1H, imidazole CH), 7.44 (s, 1H, CONH), 7.21 (s, 1H, CONH), 6.5 (s, 1H, CH), 6.92 (d, *J* = 5.1 Hz, 1H, 1'-H), 6.10–5.90 (brs, 2H, 2 OH), 5.55–4.90 (brs, 5H, OH+ 2 NH₂), 4.10–3.81 (m, 2H, 2'-H, and 3'-H), 3.62–3.38 (m, 3H, 4'-, 5'- and 5''-H); ¹³C NMR (DMSO-*d*₆, 75 MHz) δ 164.9, 161.0, 159.6, 134.4, 131.5, 126.2, 87.9, 83.5, 77.9, 71.1, 60.8, 57.9; HRMS (FAB) calcd. for C₁₂H₁₈N₈O₅, 355.1401 (MH⁺); observed *m/z* 355.1418 (MH⁺).
27. Zhang N, Chen HM, Koch V, Schmitz H, Liao CL, Bretner M, Bhadti VS, Fattom AI, Naso RB, Hosmane RS, Borowski P. J Med Chem 2003;46:4149. [PubMed: 12954067]
28. Zhang N, Chen HM, Koch V, Schmitz H, Minczuk M, Stepien P, Fattom AI, Naso RB, Kalicharran K, Borowski P, Hosmane RS. J Med Chem 2003;46:4776. [PubMed: 14561097]
29. Borowski P, Lang M, Haag A, Schmitz H, Choe J, Chen HM, Hosmane RS. Antimicrob Agents Chemother 2002;46:1231. [PubMed: 11959550]

30. Borowski P, Niebuhr A, Mueller O, Bretner M, Felczak K, Kulikowski T, Schmitz H. *J Virol* 2001;75:3220. [PubMed: 11238848]
31. Gwack Y, Kim DW, Han JH, Choe J. *Biochem Biophys Res Commun* 1996;225:654. [PubMed: 8753814]
32. Kim DW, Gwack Y, Han JH, Choe J. *Biochem Biophys Res Commun* 1995;215:160. [PubMed: 7575585]
33. Chang YS, Liao CL, Tsao CH, Chen MC, Liu CI, Chen LK, Lin YL. *J Virol* 1999;73:6257. [PubMed: 10400716]
34. Champreda V, Khumthong R, Subsin B, Angsuthanasombat C, Panyim S, Katzenmeier G. *J Biochem Mol Biol* 2000;33:294.
35. Marsch GA, Ward RL, Colvin M, Turteltaub KW. *Nucleic Acids Res* 1994;22:5408. [PubMed: 7816632]
36. Morales JC, Kool ET. *Biochemistry* 2000;39:12979. [PubMed: 11041863]

$\text{R} = \text{CH}_2\text{C}_6\text{H}_5, \text{CH}_2\text{OCH}_2\text{C}_6\text{H}_5, \text{Deoxyribosyl}$

Scheme 1.

Scheme 2.

Table 1

Inhibitory effect of nucleoside **4** against the helicase activity of WNV, HCV, JEV, and DENV NTPases/helicases, using a DNA substrate.^a

WNV IC ₅₀ (μM) ^b	HCV IC ₅₀ (μM) ^b	JEV IC ₅₀ (μM) ^b	DENV IC ₅₀ (μM) ^b
23	37	>500	>430

^aThe helicase activity was determined as a function of increasing concentrations of the compound in the presence of ATP adjusted to the respective K_M values equal to 9.5 μM, 105 μM, 4.2 μM, and 165 μM of WNV, HCV, JEV, and DENV NTPase/helicase, and 4.7 pM of DNA substrate.

^bThe inhibitory effect of the compound was expressed as the concentration at which 50% of the unwinding activity was observed. The helicase activity of the enzyme measured in the absence of the compound was referred to as 100%. The term IC₅₀ is defined as the concentration of the compound required for 50% inhibition of enzyme activity.